BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29545329)

  • 1. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
    Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE
    Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
    Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
    Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.
    Etra A; El Jurdi N; Katsivelos N; Kwon D; Gergoudis S; Morales G; Spyrou N; Kowalyk S; Aguayo-Hiraldo P; Akahoshi Y; Ayuk F; Baez J; Betts BC; Chanswangphuwana C; Chen YB; Choe H; DeFilipp Z; Gleich S; Hexner E; Hogan WJ; Holler E; Kitko CL; Kraus S; Al Malki M; MacMillan M; Pawarode A; Quagliarella F; Qayed M; Reshef R; Schechter T; Vasova I; Weisdorf D; Wölfl M; Young R; Nakamura R; Ferrara JLM; Levine JE; Holtan S
    Blood Adv; 2024 Jun; 8(12):3284-3292. PubMed ID: 38640195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
    Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
    Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
    Hartwell MJ; Özbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Wölfl M; Mielke S; Pawarode A; Chen YB; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kröger N; Locatelli F; Morales G; Nakamura R; Reshef R; Rösler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JL
    JCI Insight; 2017 Feb; 2(3):e89798. PubMed ID: 28194439
    [No Abstract]   [Full Text] [Related]  

  • 6. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
    Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
    Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.
    McDonald GB; Tabellini L; Storer BE; Martin PJ; Lawler RL; Rosinski SL; Schoch HG; Hansen JA
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1257-1263. PubMed ID: 28478120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
    Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
    Front Immunol; 2019; 10():2338. PubMed ID: 31649665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
    Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
    Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
    Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
    Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
    Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
    Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
    Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
    Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
    Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.
    Srinagesh HK; Özbek U; Kapoor U; Ayuk F; Aziz M; Ben-David K; Choe HK; DeFilipp Z; Etra A; Grupp SA; Hartwell MJ; Hexner EO; Hogan WJ; Karol AB; Kasikis S; Kitko CL; Kowalyk S; Lin JY; Major-Monfried H; Mielke S; Merli P; Morales G; Ordemann R; Pulsipher MA; Qayed M; Reddy P; Reshef R; Rösler W; Sandhu KS; Schechter T; Shah J; Sigel K; Weber D; Wölfl M; Wudhikarn K; Young R; Levine JE; Ferrara JLM
    Blood Adv; 2019 Dec; 3(23):4034-4042. PubMed ID: 31816061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification.
    Etra A; Gergoudis S; Morales G; Spyrou N; Shah J; Kowalyk S; Ayuk F; Baez J; Chanswangphuwana C; Chen YB; Choe H; DeFilipp Z; Gandhi I; Hexner E; Hogan WJ; Holler E; Kapoor U; Kitko CL; Kraus S; Lin JY; Al Malki M; Merli P; Pawarode A; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Van Hyfte G; Weber D; Wölfl M; Young R; Özbek U; Ferrara JLM; Levine JE
    Blood Adv; 2022 Jun; 6(12):3707-3715. PubMed ID: 35443021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
    MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Murata M; Nakasone H; Kanda J; Nakane T; Furukawa T; Fukuda T; Mori T; Taniguchi S; Eto T; Ohashi K; Hino M; Inoue M; Ogawa H; Atsuta Y; Nagamura-Inoue T; Yabe H; Morishima Y; Sakamaki H; Suzuki R
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1183-9. PubMed ID: 23676716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
    Hotta M; Satake A; Yoshimura H; Fujita S; Katayama Y; Ota S; Hanamoto H; Oyake T; Ito S; Okada M; Nakanishi T; Ito T; Ishii K; Nomura S
    Transplant Cell Ther; 2021 Aug; 27(8):660.e1-660.e8. PubMed ID: 33989832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant.
    Aziz MD; Shah J; Kapoor U; Dimopoulos C; Anand S; Augustine A; Ayuk F; Chaudhry M; Chen YB; Choe HK; Etra A; Gergoudis S; Hartwell MJ; Hexner EO; Hogan WJ; Kitko CL; Kowalyk S; Kröger N; Merli P; Morales G; Nakamura R; Ordemann R; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Schreiner E; Srinagesh H; Wölfl M; Wudhikarn K; Yanik G; Young R; Özbek U; Ferrara JLM; Levine JE
    Leukemia; 2020 Jul; 34(7):1898-1906. PubMed ID: 32020045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease.
    Rodriguez-Otero P; Porcher R; Peffault de Latour R; Contreras M; Bouhnik Y; Xhaard A; Andreoli A; Ribaud P; Kapel N; Janin A; Socié G; Robin M
    Blood; 2012 Jun; 119(24):5909-17. PubMed ID: 22555971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.